ロード中...
Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
Hereditary transthyretin‐mediated (hATTR) amyloidosis is a rare, inherited, progressively debilitating, and often fatal disease caused by deposition of mutated transthyretin (TTR) protein. Patisiran is an RNA interference therapeutic comprising a novel small interfering ribonucleic acid (ALN‐18328)...
保存先:
| 出版年: | J Clin Pharmacol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7187331/ https://ncbi.nlm.nih.gov/pubmed/31777097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1553 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|